Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NSD2 | O96028 | 7/20 | 1.00 |
| ▸ | DOT1L | Q8TEK3 | 5/20 | 1.00 |
| ▸ | NNMT | P40261 | 5/20 | 1.00 |
| ▸ | CARM1 | Q86X55 | 5/20 | 1.00 |
| ▸ | SETD7 | Q8WTS6 | 4/20 | 1.00 |
| ▸ | EHMT2 | Q96KQ7 | 4/20 | 1.00 |
| ▸ | PRMT1 | Q99873 | 3/20 | 1.00 |
| ▸ | PCMT1 | P22061 | 2/20 | 1.00 |
| ▸ | SETD2 | Q9BYW2 | 2/20 | 1.00 |
| ▸ | TRDMT1 | O14717 | 2/20 | 1.00 |
| ▸ | PRMT5 | O14744 | 2/20 | 1.00 |
| ▸ | INMT | O95050 | 2/20 | 1.00 |
| ▸ | METTL3 | Q86U44 | 2/20 | 1.00 |
| ▸ | EHMT1 | Q9H9B1 | 2/20 | 1.00 |
| ▸ | METTL14 | Q9HCE5 | 2/20 | 1.00 |
| ▸ | RNMT | O43148 | 1/20 | 1.00 |
| ▸ | TPMT | P51580 | 1/20 | 1.00 |
| ▸ | NSD1 | Q96L73 | 1/20 | 1.00 |
| ▸ | NSD3 | Q9BZ95 | 1/20 | 1.00 |
| ▸ | FASN | P49327 | 3/20 | 0.75 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Sinefungin SCHEMBL30779328 | 1.00 | NSD2 (1.00) | NSD2DOT1LNNMTCARM1SETD7 | |
| Sinefungin SCHEMBL19421010 | 1.00 | NSD2 (1.00) | NSD2DOT1LNNMTCARM1SETD7 | |
| Sinefungin SCHEMBL38665462 | 1.00 | NSD2 (1.00) | NSD2DOT1LNNMTCARM1SETD7 | |
| Sinefungin SCHEMBL10400321 | 1.00 | NSD2 (1.00) | NSD2DOT1LNNMTCARM1SETD7 | |
| Sinefungin SCHEMBL24478706 | 1.00 | NSD2 (1.00) | NSD2DOT1LNNMTCARM1SETD7 | |
| Sinefungin SCHEMBL23607779 | 1.00 | NSD2 (1.00) | NSD2DOT1LNNMTCARM1SETD7 | |
| Sinefungin SCHEMBL167609 | 1.00 | NSD2 (1.00) | NSD2DOT1LNNMTCARM1SETD7 | |
| Sinefungin SCHEMBL3400839 | 1.00 | NSD2 (1.00) | NSD2DOT1LNNMTCARM1SETD7 | |
| Sinefungin SCHEMBL20992057 | 1.00 | NSD2 (1.00) | NSD2DOT1LNNMTCARM1SETD7 | |
| Sinefungin SCHEMBL19418813 | 1.00 | NSD2 (1.00) | NSD2DOT1LNNMTCARM1SETD7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2018075947-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF RNA VIRAL INFECTIONS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2018-04-26 | — | — | WO | disclosed |
| US-20180010132-A1 | INHIBITION OF PRMT5 TO TREAT MTAP-DEFICIENCY-RELATED DISEASES | NOVARTIS AG (CH) | 2018-01-11 | — | — | US | disclosed |
| US-20170283807-A1 | COMPOSITIONS AND METHODS FOR DIAGNOSIS AND TREATMENT OF PROSTATE CANCER | NOVARTIS AG (CH) | 2017-10-05 | — | — | US | disclosed |
| US-20160201063-A1 | EPIGENETIC REGULATORS OF FRATAXIN | RANA THERAPEUTICS, INC. (US) | 2016-07-14 | — | — | US | disclosed |
| US-20160201063-A1 | EPIGENETIC REGULATORS OF FRATAXIN | RANA THERAPEUTICS, INC. (US) | 2016-07-14 | — | — | US | disclosed |
| US-20080132525-A1 | isoforms DNMT1 and DNMT3b2; for example: 2-amino-4-(((2S,3S,4R,5R)-3,4-dihydroxy-5-(6-(phenethylamino)-9H-purin-9-yl)-tetrahydrofuran-2-yl)methylthio)butanoic acid | METHYLGENE INC. (CA) | 2008-06-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180010132-A1 | INHIBITION OF PRMT5 TO TREAT MTAP-DEFICIENCY-RELATED DISEASES | PRMT5, PRMT1, PRMT6 | NSD2 241/4885DOT1L 24/4885NNMT 30/4885 |
| US-20080132525-A1 | isoforms DNMT1 and DNMT3b2; for example: 2-amino-4-(((2S,3S,4R,5R)-3,4-dihydroxy-5-(6-(phenethylamino)-9H-purin-9-yl)-tetrahydrofuran-2-yl)methylthio)butanoic acid | DNMT3B, DNMT1, DNMT3L | NSD2 239/4885DOT1L 24/4885NNMT 81/4885 |
| US-20170283807-A1 | COMPOSITIONS AND METHODS FOR DIAGNOSIS AND TREATMENT OF PROSTATE CANCER | PRMT5, PRMT1, PRMT3 | NSD2 225/4885DOT1L 45/4885NNMT 521/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.